What is the appropriate dosing, contraindications, and side effects of bupropion for treating depression and aiding smoking cessation?

Bupropion for Depression and Smoking Cessation

Bupropion is highly effective for both smoking cessation and depression treatment, with standard dosing of 150 mg once daily for 3 days, then 150 mg twice daily (maximum 300 mg/day), but requires careful screening for seizure risk factors and absolute contraindications before prescribing.

Dosing Regimen

For Smoking Cessation

Start bupropion 1-2 weeks before the target quit date 1:

• Days 1-3: 150 mg orally once daily
• Day 4 through 7-12 weeks: 150 mg orally twice daily (if tolerated)
• Maximum dose: 300 mg per day
• Duration: 7-12 weeks initially; may extend to 6 months-1 year for continued cessation 1

For Major Depressive Disorder

Per FDA labeling 2:

• Starting dose: 150 mg once daily
• After 4 days: May increase to 300 mg once daily
• Usual target dose: 300 mg once daily
• Increase dose gradually to reduce seizure risk

Dose Adjustments

• Moderate to severe hepatic impairment: 150 mg every other day 2
• Mild hepatic impairment: Consider reducing dose and/or frequency 2
• Renal impairment: Consider reducing dose and/or frequency 2

Absolute Contraindications

Do not prescribe bupropion if any of the following are present 1, 2:

1. Seizure disorder (current or history)
2. Seizure risk factors:
   • Stroke
   • Brain metastases
   • History of head trauma
3. Current or prior bulimia or anorexia nervosa
4. Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
5. MAOI use (within 14 days) or concurrent linezolid/IV methylene blue 2
6. Closed-angle glaucoma 1
7. Known hypersensitivity to bupropion 2
8. Concurrent tamoxifen use 1

Side Effects and Safety Profile

Common Side Effects (≥5% incidence) 2

• Dry mouth
• Insomnia
• Nausea
• Dizziness
• Headache
• Agitation/anxiety
• Tremor
• Sweating

Serious Adverse Events

Seizure Risk: Approximately 1 in 1,000 (0.1%) 2, 3. This is dose-related and can be minimized by:

• Not exceeding 300 mg/day for smoking cessation
• Gradual dose titration
• Avoiding in patients with seizure risk factors

Neuropsychiatric Effects: Although historically concerning, high-quality evidence from the EAGLES trial (n=8,058) found no significant increase in neuropsychiatric adverse events with bupropion compared to nicotine patches or placebo in smokers with or without psychiatric disorders 1. However, the FDA black box warning remains for suicidal thoughts and behaviors, particularly in patients under 24 years 2.

Allergic Reactions: Approximately 3% incidence, ranging from 1 in 10,000 to 1 in 1,000 for serious reactions 3

Cardiovascular Effects: Monitor blood pressure before and during treatment; avoid in uncontrolled hypertension 2

Monitoring Requirements

1. Screen for:

   • Bipolar disorder (risk of mania/hypomania activation) 2
   • Seizure history or risk factors
   • Current psychiatric symptoms
   • Blood pressure

2. During treatment, monitor for:

   • Neuropsychiatric symptoms (depression, suicidal ideation, agitation, hostility, psychosis) 1, 2
   • Blood pressure changes 2
   • Emergence of angle-closure glaucoma symptoms 2

3. Discontinue immediately if:

   • Seizure occurs
   • Serious neuropsychiatric symptoms develop
   • Allergic reaction occurs

Clinical Efficacy

Smoking Cessation

Bupropion increases long-term smoking cessation rates with high-certainty evidence (RR 1.64,95% CI 1.52-1.77; 45 studies, 17,866 participants) 4. This translates to helping approximately one in five smokers quit 5.

Comparative effectiveness:

• Inferior to varenicline (RR 0.71,95% CI 0.64-0.79) 4
• Equivalent to NRT (RR 0.99,95% CI 0.91-1.09) 4
• Combination with NRT: Insufficient evidence of superiority over NRT alone 1, 4

Depression

Bupropion at 300 mg daily is effective for long-term treatment of recurrent major depression 6. It has lower rates of sexual dysfunction compared to SSRIs (particularly fluoxetine and sertraline) 7, making it preferable for patients concerned about sexual side effects.

Special Populations

Patients with Depression

Consider bupropion as first-line for patients needing both smoking cessation and depression treatment 6. The EAGLES trial demonstrated safety in smokers with major depressive disorder 8, though quit rates were lower in MDD patients (31.2% vs 38.0% in non-psychiatric controls with varenicline) 8.

Patients Requiring Opioid Therapy

Do not use naltrexone-bupropion combination in patients requiring short or long-term opiates; discontinue before procedures requiring opioids (e.g., endoscopy with fentanyl) 6.

Cancer Patients

Bupropion XL and SR formulations have equivalent effectiveness and similar adverse event profiles in cancer patients 9. Both can be used safely in this population, though avoid in patients with brain metastases due to seizure risk 1.

Drug Interactions

Critical interactions 2:

• CYP2D6 substrates: Bupropion inhibits CYP2D6; reduce doses of antidepressants (venlafaxine, SSRIs, TCAs), antipsychotics (haloperidol, risperidone), beta-blockers (metoprolol), and Type 1C antiarrhythmics (propafenone, flecainide)
• CYP2B6 inducers: May require bupropion dose increase (ritonavir, efavirenz, carbamazepine, phenobarbital, phenytoin)
• Drugs lowering seizure threshold: Use extreme caution
• MAOIs: Contraindicated within 14 days

Common Pitfalls

1. Prescribing without adequate seizure risk assessment - Always screen for history of seizures, eating disorders, head trauma, brain lesions, and alcohol/benzodiazepine withdrawal
2. Exceeding maximum dose - Never exceed 300 mg/day for smoking cessation (450 mg/day maximum for depression)
3. Inadequate titration - Rapid dose escalation increases seizure risk
4. Ignoring drug interactions - Particularly important with CYP2D6 substrates
5. Discontinuing too early - Therapy should continue 7-12 weeks minimum; consider extending to 6-12 months for sustained cessation 1
6. False-positive drug screens - Bupropion can cause false-positive urine tests for amphetamines 2

Treatment Discontinuation Criteria

Stop bupropion if 1:

• Patient has not lost 5% body weight after 12 weeks (for weight loss indication)
• Seizure occurs
• Serious neuropsychiatric symptoms develop
• Severe allergic reaction occurs
• Patient requires opioid therapy